STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
12
13F, latest reported quarter
Conversions, 180 days
15
Codes C/M, not in net · $0 priced
What the filings say about CDLX
Insiders, 180 days
-$51.9K net sold
1 buyer · 2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$100.6K
4 notices
Cardlytics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Cardlytics, Inc. insiders sold a net $51.9K of stock across 299 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Jul 2, 2026.
The trade is 8.5% of the 113,850 shares held after it.
1 other insider sold within 30 days.
12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Gupta Amit sold about $42.4K of CDLX on Jul 6, 2026; 1 other insider sold within 30 days and 12 funds added in the latest 13F quarter.
299 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
CDLX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Gupta Amit
Filed 2026-10-02
$18.7K
Gupta Amit
Filed 2026-10-01
$28.1K
Gupta Amit
Filed 2026-08-18
$26.9K
Gupta Amit
Filed 2026-08-17
$26.9K
Gupta Amit
Filed 2026-07-06
$42.4K
CDLX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$34.0K position · as of 2026-06-30
0.0%
Invesco RAFI US 1500 Small-Mid ETF
$58.2K position · as of 2026-07-31
0.0%
VANGUARD COMMUNICATION SERVICES INDEX FUND
$121.4K position · as of 2026-05-31
0.0%
Goldman Sachs Absolute Return Tracker Fund
$46.1K position · as of 2026-06-30
0.0%
TETON Westwood Mighty Mites Fund
$1.1K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$215.9K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $51.9K sold by insiders over 180 days, 12 funds added last quarter, $100.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$179.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CDLX
FY Dec 2025
$233.3M
FY Dec 2024
$278.3M
FY Dec 2023
$309.2M
FY Dec 2022
$298.5M
FY Dec 2021
$267.1M
Jun 2026
$36.9M
Mar 2026
$34.3M
Dec 2025
$56.1M
Sep 2025
$52.0M
Jun 2025
$63.2M
Mar 2025
$61.9M
Dec 2024
$74.0M
Sep 2024
$67.1M
At each fiscal year end
Single quarter
Net margin, TTM
-56.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CDLX
FY Dec 2025
-44.6%
FY Dec 2024
-67.9%
FY Dec 2023
-43.7%
FY Dec 2022
-155.8%
FY Dec 2021
-48.1%
Jun 2026
-40.3%
Mar 2026
-13.1%
Dec 2025
-15.6%
Sep 2025
-139.7%
Jun 2025
-14.7%
Mar 2025
-21.5%
Dec 2024
-20.7%
Sep 2024
-216.5%
At each fiscal year end
Single quarter
Free cash flow, TTM
$463.0K
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CDLX
FY Dec 2025
$8.8M
FY Dec 2024
-$10.4M
FY Dec 2023
-$852.0K
FY Dec 2022
-$55.1M
FY Dec 2021
-$41.6M
Jun 2026
-$8.6M
Mar 2026
-$5.7M
Dec 2025
$13.0M
Sep 2025
$1.7M
Jun 2025
$903.0K
Mar 2025
-$6.8M
Dec 2024
$2.9M
Sep 2024
$878.0K
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity CDLX
FY Dec 2025
n/a
FY Dec 2024
3.71x
FY Dec 2023
1.91x
FY Dec 2022
1.07x
FY Dec 2021
0.27x
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
4.43x
Mar 2025
4.05x
Dec 2024
3.71x
Sep 2024
3.72x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.00x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end)
Cash flow to debt CDLX
FY Dec 2025
0.04x
FY Dec 2024
-0.03x
FY Dec 2023
-0.00x
FY Dec 2022
-0.24x
FY Dec 2021
-0.21x
Jun 2026
0.00x
Mar 2026
0.05x
Dec 2025
0.04x
Sep 2025
-0.00x
Jun 2025
-0.00x
Mar 2025
0.01x
Dec 2024
-0.03x
Sep 2024
-0.03x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-472.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CDLX
FY Dec 2025
-327.6%
FY Dec 2024
-184.6%
FY Dec 2023
-77.9%
FY Dec 2022
-103.1%
FY Dec 2021
-30.3%
Jun 2026
-472.1%
Mar 2026
-316.9%
Dec 2025
-327.6%
Sep 2025
-340.1%
Jun 2025
-136.2%
Mar 2025
-135.2%
Dec 2024
-184.6%
Sep 2024
-186.3%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-33.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CDLX
FY Dec 2025
-30.7%
FY Dec 2024
-39.1%
FY Dec 2023
-21.3%
FY Dec 2022
-47.6%
FY Dec 2021
-15.2%
Jun 2026
-33.8%
Mar 2026
-30.1%
Dec 2025
-30.7%
Sep 2025
-31.9%
Jun 2025
-40.9%
Mar 2025
-38.0%
Dec 2024
-39.1%
Sep 2024
-53.1%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital CDLX
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed CDLX
FY Dec 2025
n/a
FY Dec 2024
-60.5%
FY Dec 2023
-32.1%
FY Dec 2022
-66.4%
FY Dec 2021
-19.2%
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
-47.4%
Jun 2025
-53.7%
Mar 2025
-52.2%
Dec 2024
-60.5%
Sep 2024
-83.0%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CDLX
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$167.0M
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
Enterprise value CDLX
FY Dec 2025
$781.9M
FY Dec 2024
$2.1B
FY Dec 2023
$3.8B
FY Dec 2022
$2.0B
FY Dec 2021
$21.9B
Jun 2026
$415.0M
Mar 2026
$746.6M
Dec 2025
$781.9M
Sep 2025
$1.5B
Jun 2025
$1.1B
Mar 2025
$1.2B
Dec 2024
$2.1B
Sep 2024
$1.8B
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.4%
TTM free cash flow over market value at close 2026-10-23
FCF yield CDLX
FY Dec 2025
+1.4%
FY Dec 2024
-0.6%
FY Dec 2023
-0.0%
FY Dec 2022
-2.9%
FY Dec 2021
-0.2%
Jun 2026
+0.2%
Mar 2026
+1.7%
Dec 2025
+1.4%
Sep 2025
-0.1%
Jun 2025
-0.3%
Mar 2025
+0.1%
Dec 2024
-0.6%
Sep 2024
-0.7%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CDLX
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
CDLX ranks highest on insider conviction (72nd percentile) and risk and compliance (34th), and lowest on growth (11th), among Software & IT peers.
Profitability
15
Inputs
Return on equity-472.1% · 4 pct, sector of 286
Return on assets-33.8% · 26 pct, sector of 381
Return on invested capitalthe filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employedthe filed year and its quarters do not reconcile, so the trailing figure is withheld
Financial health
33
Inputs
Debt to equityequity is zero or negative, the ratio has no meaning
Cash flow to debt0.00x · 33 pct, sector of 241
Growth
11
Inputs
Revenue growth, YoY-16.9% · 15 pct, sector of 480
Backlog growth, YoY-45.9% · 7 pct, sector of 182
Insider conviction
72
Inputs
Net Form 4 buying (codes P and S), 180d-$52K · 75 pct, sector of 285
Insider buyers, 180d1 · 69 pct, sector of 290
Institutional and government
21
Inputs
Funds adding, latest quarter12 · 21 pct, sector of 415
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
34
Inputs
Short interest, % of float+11.5% · 21 pct, sector of 530
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-K+11.7% · 47 pct, sector of 316
1 not measured: US patents
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CDLX filings, in plain words
Are Cardlytics insiders buying or selling CDLX?
In the 180 days to 2026-10-27, Cardlytics insiders were net sellers, a net $51.9K: $129.0K of purchases and $180.9K of sales reported on Form 4, by 1 buyer and 2 sellers.
Are there planned insider sales of CDLX?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $100.6K of stock; the latest, by Gupta Amit, was filed 2026-10-02.
Read the full summary
In the 180 days to 2026-10-27, Cardlytics insiders were net sellers of CDLX, a net $51.9K across purchases and sales reported on Form 4 by 1 buyer and 2 sellers. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $100.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.